These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 477224)

  • 1. Studies on mineralocorticoid 'escape' in cirrhosis.
    Wilkinson SP; Smith IK; Moodie H; Poston L; Williams R
    Clin Sci (Lond); 1979 May; 56(5):401-6. PubMed ID: 477224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in the plasma levels of atrial natriuretic peptides during mineralocorticoid escape in man.
    Cappuccio FP; Markandu ND; Buckley MG; Sagnella GA; Shore AC; MacGregor GA
    Clin Sci (Lond); 1987 May; 72(5):531-9. PubMed ID: 2953526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension.
    La Villa G; Salmerón JM; Arroyo V; Bosch J; Ginés P; García-Pagán JC; Ginés A; Asbert M; Jiménez W; Rivera F
    Gastroenterology; 1992 Jun; 102(6):2114-9. PubMed ID: 1587432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Renal resistance to atrial natriuretic factor as a cause of the escape failure phenomenon in patients with non-ascitic liver cirrhosis].
    Tesar V; Spicák J; Horký K; Zabka J; Widimský J; Jedlicka J; Marecek Z
    Cas Lek Cesk; 1994 Feb; 133(4):111-5. PubMed ID: 8137382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potassium supplementation ameliorates mineralocorticoid-induced sodium retention.
    Krishna GG; Kapoor SC
    Kidney Int; 1993 May; 43(5):1097-103. PubMed ID: 8510388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mineralocorticoid-resistant renal hyperkalemia without salt wasting (type II pseudohypoaldosteronism): role of increased renal chloride reabsorption.
    Schambelan M; Sebastian A; Rector FC
    Kidney Int; 1981 May; 19(5):716-27. PubMed ID: 7026872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of plasma renin activity in evaluating the adequacy of mineralocorticoid replacement in primary adrenal insufficiency.
    Flad TM; Conway JD; Cunningham SK; McKenna TJ
    Clin Endocrinol (Oxf); 1996 Nov; 45(5):529-34. PubMed ID: 8977748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mineralocorticoid escape in man: role of renal prostaglandins.
    Dürr J; Favre L; Gaillard R; Riondel AM; Vallotton MB
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):474-80. PubMed ID: 7041504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of atrial natriuretic peptide (ANP) during mineralocorticoid escape in normal man.
    Wambach G; Götz S; Suckau G; Kaufmann W
    Klin Wochenschr; 1986; 64 Suppl 6():53-7. PubMed ID: 2948064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced natriuretic effect of atrial natriuretic factor during mineralocorticoid escape in humans.
    Gaillard CA; Koomans HA; Rabelink TJ; Braam B; Boer P; Dorhout Mees EJ
    Hypertension; 1988 Oct; 12(4):450-6. PubMed ID: 2971618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of administered mineralocorticoids or ACTH in pregnant women. Attenuation of kaliuretic influence of mineralocorticoids during pregnancy.
    Ehrlich EN; Lindheimer MD
    J Clin Invest; 1972 Jun; 51(6):1301-9. PubMed ID: 4336938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of mineralocorticoid administration on urine free dopamine in man.
    Oates NS; Perkins CM; Lee MR
    Clin Sci (Lond); 1980 Jan; 58(1):77-82. PubMed ID: 6986226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal sodium retention in cirrhosis: relation to aldosterone and nephron site.
    Wilkinson SP; Jowett TP; Slater JD; Arroyo V; Moodie H; Williams R
    Clin Sci (Lond); 1979 Feb; 56(2):169-77. PubMed ID: 477199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal handling of calcium and phosphate during mineralocorticoid administration in normal subjects.
    Cappuccio FP; Markandu ND; MacGregor GA
    Nephron; 1988; 48(4):280-3. PubMed ID: 3362272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of plasma renin activity to monitor mineralocorticoid treatment in dogs with primary hypoadrenocorticism: desoxycorticosterone versus fludrocortisone.
    Baumstark ME; Nussberger J; Boretti FS; Baumstark MW; Riond B; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2014; 28(5):1471-8. PubMed ID: 25274440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacological action of 9alpha-fluorohydrocortisone as a mineralocorticoid].
    Sekihara H
    Nihon Rinsho; 1994 Mar; 52(3):583-6. PubMed ID: 8164353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escape from the sodium-retaining effects of mineralocorticoids: is there a role for dopamine?
    Coruzzi P
    J Clin Endocrinol Metab; 1994 Feb; 78(2):455-8. PubMed ID: 8106635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma renin activity in alcoholic liver disease.
    Rector WG; Lewis FW; Adair OV; Robertson AD
    Am J Med; 1992 May; 92(5):485-93. PubMed ID: 1533748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lithium clearance in mineralocorticoid escape in humans.
    Boer WH; Koomans HA; Dorhout Mees EJ
    Am J Physiol; 1987 Mar; 252(3 Pt 2):F382-6. PubMed ID: 3826382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis.
    Johannsson G; Sverrisdóttir YB; Ellegård L; Lundberg PA; Herlitz H
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1743-9. PubMed ID: 11932310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.